Abstract: Biomimetic calcium phosphate ceramics with excellent bio-absorption and osteoinduction were designed by the partial dissolution-precipitation (PDP) treatment. Beta-tricalcium phosphate ( -TCP) ceramics with single phase were transformed into monetite, hydroxyapatite (HAp) and -TCP phases by the PDP treatment. The PDP--TCP ceramics had a specific surface area of 22.5 m 2 /g and porosities of 60-80 %. Changes in microstructure of the ceramics before and after PDP treatment influenced body fluid permeation, release characteristics of bone morphogenetic protein-2 (BMP-2) and osteoinduction.
Introduction
A human clinical trial using bone morphogenetic protein-2 (BMP-2) was incorporated in an absorbable collagen sponge (ACS) for augmentation of localized osseous defect. Statistically, significant dose-response relationships were detected using CT scan for the measurement of bone height responses. However, no bone formation was observed without adding BMP-2 over 150 g 1) . The in vivo release of 125 I-labeled BMP-2 from ACS was investigated using rat ectopic model. The ACS showed high release rate of BMP-2 (the release time corresponding to the half amount (t 1/2) of BMP-2: day 2.1) 2) . An optimized delivery system might improve the osteoinduction of the device, while reducing the loading amount of BMP as much as possible, which offers double advantages of being safer as well as less expensive 3) . Several reports indicated that too rapid release of BMP-2 decreased osteoinduction while high retention of BMP-2 elicited more bone formation 4, 5) . It is likely that an extremely low dose of BMP-2 is enough to enhance osteoinduction if BMP-2 is appropriately delivered to the site of action 6) .
Thus, it is necessary to develop a carrier for the controlled release of biologically active BMP-2 over an extended time period. Furthermore, we believe that ideal scaffolds for bone engineering should be bioabsorbable, mimetic and hydrophilic which can allow the permeation of liquid components, such as blood and/or operation 8, 9) . The b-HAp ceramics with a porosity of 60-80%
and specific surface area of 1-2 m 2 /g were partially dissolved and . Moreover, ectopic bone formation occurred in fg-HAp/BMP-2 (0.5, 1.0, 5.0 g) ceramics at 3 weeks, while only bone induction was found in b-HAp/BMP-2 (5.0 g) ceramics. Histological observation showed body fluid permeation into fg-HAp as densely stained areas and nano-microcracks were noted on the fg-HAp surface. The densely stained areas were immunopositive for albumin 7) . Thus, PDP treatment enhanced osteoinduction, body fluid permeation and gradual release of BMP-2. As a result, fgHAp/BMP-2 ceramics had an ideal BMP-2 release curve and osteoinductive property at a low dose of BMP-2. However, the practice of using a material derived from bovine bone has significant hurdle to overcome.
In experimental and clinical cases, porous HAp and betatricalcium phosphate ( -TCP) have been widely used because of their inherent osteoinductivity 11, 12) . However, since synthetic HAp is not practically degraded under physical condition, it remains inside the regenerated bone tissue. One of the advantages of -TCP is its biodegradability, though it is brittle compared to HAp. Therefore, we tried to improve a commercial bioceramic into a more effective biomaterial called partially dissolved and precipitated beta-tricalcium phosphate (PDP--TCP) with the properties of fg-HAp by adding PDP treatment. The purpose of this study was to modify the microstructure of bioceramics and enhance osteoinduction by adopting specific PDP treatment.
Materials and Methods
Preparation and physicochemical characterization of calcium phosphate ceramics fg-HAp ceramics were fabricated in the same method as described previously 8, 9) . Briefly, bovine spongy and cortical bones were cut into cubic samples, which were boiled and calcined at 800-1100℃for 24 h in air to remove organic components. The spongy-derived bulk of HAp (b-HAp) was partially dissolved into a nitric acid aqueous solution, while the cortical-derived bulk of HAp was completely dissolved into another nitric acid aqueous solution. By adding the treatment of partial dissolution, nanomicropores were formed on the material surface.
After the two solutions were mixed, an ammonium aqueous solution was added with stirring, and nano-microcrystals were carefully reprecipitated on the nano-micropores of the spongy bHAp at pH 10.5 and 25℃ for 24 h. The artificial modified spongy b-HAp was filtrated and washed with distilled water and dried to fabricate the fg-HAp ceramics (porosity: 60-80%, pore diameter: macropores 100-600mm, nano-micropores10-160nm).
Precipitated HAp particles formed spherical moss like-grains (1-2 m) with needle-like nano-microcrystals (10nm) on the fg-HAp surface. The new ceramics were fabricated based on same concept. Commercial -TCP (Osferion ® , sintering temperature: 1050 ℃, porosity: 60-80%, pore size: 100-400 m, surface area: 4m 2 / g) was kindly provided by OLYMPUS Co., Tokyo, Japan (Fig.1 ).
Cortical bone of bovine femur (Holstein bull, Hokkaido prefecture, 
Analysis of the release of BMP-2

Radioiodination of BMP-2
H u ma n r e c o mb i n a n t B M P -2 ( r h B M P -2 , As t e l l a s Pharmaceutical Co., Tokyo, Japan) underwent radioiodination according to the standard method 13) . Briefly, 10 l of Na surrounding tissues were measured to evaluate the time profile of in vivo BMP-2 retention of ceramics. Statistical analysis was done using Student t-test. A p-value < 0.05 was considered significant. The data of fg-HAp/BMP-2 used was from a previous study 10) .
Analysis of BMP-2 dose-response bone formation Implantation and histopathological evaluation of the ceramics
Ceramics/BMP-2, rhBMP-2 (Astellas Pharmaceutical Co., Tokyo, Japan) solution was prepared in the following manner. A total of 10 ml of various concentrations of BMP-2 solution (0.05, served as negative controls for a total of 6 groups. Thirty-six Wistar rats (male, 4 week-old, 70g body weight, 6 rats per group) were subjected to intraperitoneal anesthesia with pentobarbital sodium (4mg/100g body weight). Under sterile conditions, vertical incisions were made on the skin at the back region, and two subcutaneous pockets were prepared by blunt dissection. The 
Results
Physicochemical characterization of calcium phosphate ceramics
X-ray analysis of PDP-β-TCP ceramics revealed that it is composed of monetite, hydroxyapatite and β-TCP. β-TCP ceramics consist of a single phase of β-TCP (Fig.2) . The pore diameter and accumulated pore volume increased with PDP treatment compared to the untreated ceramics (Fig.3) . Table 1 Table 2 . In 5.0 g BMP-2 group, fg-HAp/BMP-2 (p<0.04) and -TCP/BMP-2 (p<0.05) ceramics showed significant differences compared to b-HAp/BMP-2 ceramics. In PDP--TCP/ BMP-2 ceramics, the 1.0 g (p<0.04) and 0.5 g BMP-2 (p<0.02) groups showed significant differences compared to b-HAp/BMP-2 ceramics. Furthermore, PDP--TCP/BMP-2 ceramics showed significant difference compared to -TCP/BMP-2 ceramics in 0.5 g BMP-2 group (p<0.01).
Release of BMP-2
BMP-2 dose-response of bone formation Histomorphometrical analysis
Histological evaluation
Histological examination of the de novo induced bone (Fig.5,  Fig.6 and Fig.7 ) confirmed interesting differences in each ceramics. Numerous bone including bone marrow and body fluid permeation into the ceramics were observed in fg-HAp/BMP-2, -TCP/BMP-2 and PDP--TCP/BMP-2 ceramics (Fig.5 (b) , (c), Fig.5 (a) ). The fg-HAp was phagocytosed by osteoclasts from the inside of the mass of r-HAp and fg-HAp. Osteoblasts formed new bone on the surface of r-HAp and in the mass of fgHAp (Fig.5 (c) ). r-HAp or reprecipitated--TCP (r--TCP) crystals were observed on the ceramic surfaces as densely stained areas (Fig.5 (c) , Fig.7 (b), (c) ). Nano-microcracks were observed in fgHAp/BMP-2 ceramics (Fig.5 (b), (c), (d) ). On the other hand, extensive mosaic appearances were confirmed in PDP--TCP/ BMP-2 ceramics compared to -TCP/BMP-2 ceramics (Fig.6 , Fig.7 (b), (c) ). The apparent histological changes were observed in ceramics treated with PDP (fg-HAp/BMP-2 and PDP--TCP/ BMP-2 ceramics) compared to the untreated ceramics. (Fig.8) . The PDP--TCP retained plate aggregated crystal with small grain of 0.1 m in size (Fig.1) . By PDP treatment, grain size of the ceramics became smaller and the surface areas became larger. After PDP treatment, surface areas increased remarkably and the apparent differences in fg-HAp and PDP--TCP ceramics were observed in SEM photographs. Interestingly, the x-ray analysis showed that PDP--TCP ceramics consisted of mixed phases of monetite, hydroxyapatite and -TCP (Fig.2) . The PDP treatment could have changed the composition of the ceramic surface. Changes in microstructure of the ceramics before and after PDP treatment might have influenced the release of BMP-2, osteoinduction and body fluid permeation. The results showed that fg-HAp/BMP-2 ceramics retained much BMP-2 than other ceramics in all durations. In fg-HAp/BMP-2 and PDP--TCP/BMP-2 ceramics, the t 1/2 of BMP-2 was prolonged for about 14 and 7 times respectively compared to the ceramics without PDP treatment. Statistical analysis showed significant differences of BMP-2 retention between fg-HAp/BMP-2 ceramics and b-HAp/ BMP-2 ceramics at day 1 (p<0.01), 3 (p<0.04) and 7 (p<0.04).
Discussion
Similarly, PDP--TCP ceramics showed significant difference of BMP-2 retention compared to â-TCP/BMP-2 ceramics at day 14 (p<0.04) (Fig.5) . Thus, PDP treatment improved BMP-2 retention significantly in each composition. Numerous data from literature indicated the importance of the ability of a carrier to retain sufficient BMP to enhance bone formation 16, 17) . It is suggested that controlled application of BMP-2 would allow constant and prolonged release which renders it effective over time and helps to form a chemotactic gradient necessary for cell response 18) .
Numerous studies reported the efficacy of drug delivery system (DDS) for bone regeneration [18] [19] [20] [21] . We previously investigated the efficacy of slow release of growth factors using polymer materials [19] [20] [21] [22] . Hydrogels of different biodegradable profiles from gelatin were prepared and successfully induced the biological activities of basic fibroblast growth factor (bFGF) 19) and BMP-2 (Table 1 ). In the fg-HAp/BMP-2 (5.0 g) ceramics and PDP--TCP/BMP-2 (0.5 g) ceramics, significant differences in bone areas were observed compared to b-HAp/BMP-2 (p<0.01) ceramics and -TCP/BMP-2 ceramics (p<0.01) respectively at day 21 (Table 2) . In this study, no significant difference in the retention of BMP-2 at 21 days after implantation was obtained, while significant differences in bone area were observed at the same time. Therefore, the effect of BMP-2 release must have occurred during the early days after implantation. Many reports supported this hypothesis [23] [24] [25] . Morphogenetically, it is essential that BMP-2 is biologically active during the late phase of the inflammatory reaction, which peaks 2 to 3 days after surgery. The correct timing of BMP-2 action with respect to wound healing may be more important than delayed release 23) . The dose-response and time-course study using rat ectopic bone formation assay revealed that implantation of BMP-2 with demineralized matrix carrier resulted to early bone formation. At day 5, many immature and some hypertrophic cartilage cells were present in BMP-containing implants, but no mineralizing cartilage was detected. After day 7, the chondrocytes were hypertrophic and the cartilage was mineralized 24) . The in vitro study showed osteoblast-like cells surrounding the microsurfaces within day 8 after culture 25) .
Structural parameters in the design of ceramics are thought to be critical factors in the osteoinductive potential by BMP-2.
Osteogenic cells recognize important material surface properties, like surface texture, and accordingly adjust their attachment. Studies on the response of cells to microgrooved surfaces showed that, while the response is cell type-dependent, overall, the cell elongates in the direction of the groove and then travels guided by the grooves. This phenomenon has become known as 'contact guidance' 26) . To support cellular attachment, spreading and growth, and improved cellular function, a lot of reports have been published about roughened implant surface, as well as on controlled microtopography 27) . We (Fig.9, 10) . Furthermore, effects of PDP treatment were confirmed by measuring pore size distribution of -TCP and PDP--TCP ceramics. Because of PDP treatment, pore diameter and volume increased evidently (Fig.3) . This phenomenon implies that the blood vessel and body fluid easily permeated inside the PDP--TCP ceramics. Viable bone tissue consists of ~10% body fluid, 20% organic materials, and 70% minerals including hydroxyapatite (HAp). Cells never live in dry conditions and cannot invade dry and non-nutrient areas 28) . Moreover, implanted biomaterials necessarily contact body fluid and living cells in the body. We believe that body fluid permeation into the structure is essential to the cells. Previous in vivo study showed densely stained areas and nano-microcracks in the mass of fg-HAp. This phenomenon could not be confirmed in the b-HAp/BMP-2 ceramics. The changes might have caused by PDP treatment. We detected albumin immunohistochemically in the densely stained areas and confirmed body fluid permeation into the mass of fg-HAp 8) . Albumin, a globular protein with distinct hydrophobic moieties, represents over 50% of the protein in serum, and is an efficient carrier-protein of fatty acids and sterols. In addition, albumin supplies nutrient to cells, and controls colloid osmotic pressure 29) . In this study, we confirmed densely stained areas and nano-microcracks in fgHAp/BMP-2 ceramics (Fig. 5 (b) , (c), (d)). Similarly, the PDP--TCP/BMP-2 ceramics showed densely stained areas with mosaic appearance while those areas were not observed in -TCP/BMP-2 ceramics (Fig.7) . Considering the previous studies in fg-HAp/ BMP-2 ceramics, it can be inferred that PDP treatment changed the -TCP (Osferion ® ) to PDP--TCP ceramics allowing permeation of abundant body fluid. This change might have affected the release of BMP-2 and the dose response. The body fluid permeation into the ceramics might have helped cellular activity on the mass of the ceramic.
Conclusion
In conclusion, PDP treatment of the ceramics allowed gradual release of BMP-2 and enhanced osteoinduction and body fluid permeation. By using this method, we can improve commercial bioceramics for more effective biomaterials for bone regenerative therapy or bioengineering.
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